nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—SLC6A4—attention deficit hyperactivity disorder	0.905	1	CbGaD
Levomilnacipran—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.0179	0.251	CbGeAlD
Levomilnacipran—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.0095	0.133	CbGeAlD
Levomilnacipran—CYP2J2—forebrain—attention deficit hyperactivity disorder	0.00466	0.0654	CbGeAlD
Levomilnacipran—Milnacipran—SLC6A4—attention deficit hyperactivity disorder	0.00441	0.426	CrCbGaD
Levomilnacipran—CYP2J2—cardiovascular system—attention deficit hyperactivity disorder	0.00394	0.0553	CbGeAlD
Levomilnacipran—Diethylpropion—SLC6A3—attention deficit hyperactivity disorder	0.00328	0.317	CrCbGaD
Levomilnacipran—CYP2J2—midbrain—attention deficit hyperactivity disorder	0.00308	0.0432	CbGeAlD
Levomilnacipran—CYP2J2—nervous system—attention deficit hyperactivity disorder	0.00253	0.0355	CbGeAlD
Levomilnacipran—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00251	0.0352	CbGeAlD
Levomilnacipran—CYP2J2—central nervous system—attention deficit hyperactivity disorder	0.00244	0.0342	CbGeAlD
Levomilnacipran—CYP2J2—cerebellum—attention deficit hyperactivity disorder	0.00238	0.0334	CbGeAlD
Levomilnacipran—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00221	0.031	CbGeAlD
Levomilnacipran—CYP2J2—brain—attention deficit hyperactivity disorder	0.00194	0.0271	CbGeAlD
Levomilnacipran—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.00166	0.0233	CbGeAlD
Levomilnacipran—SLC6A4—Serotonin Transporter Activity—TPH2—attention deficit hyperactivity disorder	0.00153	0.115	CbGpPWpGaD
Levomilnacipran—Pethidine—SLC6A3—attention deficit hyperactivity disorder	0.00152	0.147	CrCbGaD
Levomilnacipran—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.00136	0.0191	CbGeAlD
Levomilnacipran—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.00131	0.0184	CbGeAlD
Levomilnacipran—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00121	0.017	CbGeAlD
Levomilnacipran—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.0012	0.0168	CbGeAlD
Levomilnacipran—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.00116	0.0162	CbGeAlD
Levomilnacipran—Pethidine—SLC6A4—attention deficit hyperactivity disorder	0.00114	0.11	CrCbGaD
Levomilnacipran—SLC6A4—brain—attention deficit hyperactivity disorder	0.00104	0.0146	CbGeAlD
Levomilnacipran—SLC6A4—Serotonin Transporter Activity—MAOA—attention deficit hyperactivity disorder	0.000919	0.0694	CbGpPWpGaD
Levomilnacipran—SLC6A2—brain—attention deficit hyperactivity disorder	0.000919	0.0129	CbGeAlD
Levomilnacipran—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000872	0.0122	CbGeAlD
Levomilnacipran—CYP2C8—brain—attention deficit hyperactivity disorder	0.000755	0.0106	CbGeAlD
Levomilnacipran—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000737	0.0103	CbGeAlD
Levomilnacipran—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000669	0.00937	CbGeAlD
Levomilnacipran—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000658	0.00922	CbGeAlD
Levomilnacipran—SLC6A4—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.00065	0.0491	CbGpPWpGaD
Levomilnacipran—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000644	0.00902	CbGeAlD
Levomilnacipran—SLC6A4—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00064	0.0483	CbGpPWpGaD
Levomilnacipran—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000633	0.00888	CbGeAlD
Levomilnacipran—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000619	0.00868	CbGeAlD
Levomilnacipran—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—attention deficit hyperactivity disorder	0.000604	0.0457	CbGpPWpGaD
Levomilnacipran—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000576	0.00807	CbGeAlD
Levomilnacipran—SLC6A2—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.000559	0.0422	CbGpPWpGaD
Levomilnacipran—SLC6A2—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00055	0.0416	CbGpPWpGaD
Levomilnacipran—CYP2D6—brain—attention deficit hyperactivity disorder	0.000503	0.00705	CbGeAlD
Levomilnacipran—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000473	0.00663	CbGeAlD
Levomilnacipran—SLC6A4—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.000463	0.035	CbGpPWpGaD
Levomilnacipran—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000456	0.00639	CbGeAlD
Levomilnacipran—SLC6A2—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.000447	0.0338	CbGpPWpGaD
Levomilnacipran—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000445	0.00624	CbGeAlD
Levomilnacipran—SLC6A2—Amine compound SLC transporters—SLC6A3—attention deficit hyperactivity disorder	0.000419	0.0317	CbGpPWpGaD
Levomilnacipran—SLC6A2—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.000398	0.0301	CbGpPWpGaD
Levomilnacipran—ABCB1—brain—attention deficit hyperactivity disorder	0.000362	0.00507	CbGeAlD
Levomilnacipran—SLC6A4—Synaptic Vesicle Pathway—SNAP25—attention deficit hyperactivity disorder	0.000358	0.027	CbGpPWpGaD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000334	0.0252	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000214	0.0162	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000183	0.0138	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000179	0.0135	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000177	0.0134	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000176	0.0133	CbGpPWpGaD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000164	0.0124	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000164	0.0124	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000157	0.0119	CbGpPWpGaD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000151	0.0114	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.000149	0.0113	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000146	0.0111	CbGpPWpGaD
Levomilnacipran—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000146	0.011	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000138	0.0104	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.000133	0.01	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000119	0.00903	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000118	0.00894	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000116	0.00874	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000112	0.00849	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00011	0.00832	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000109	0.00822	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000106	0.00803	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.000105	0.00791	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000104	0.00785	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	8.98e-05	0.00678	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	8.33e-05	0.0063	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	7.45e-05	0.00563	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	7.44e-05	0.00562	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.3e-05	0.00552	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	6.84e-05	0.00517	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TPH2—attention deficit hyperactivity disorder	5.04e-05	0.00381	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.04e-05	0.00381	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—DPYD—attention deficit hyperactivity disorder	4.96e-05	0.00375	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	4.79e-05	0.00362	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	4.76e-05	0.00359	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.61e-05	0.00348	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	4.57e-05	0.00345	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	4.47e-05	0.00338	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.46e-05	0.00337	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.43e-05	0.00334	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.4e-05	0.00332	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.03e-05	0.00304	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.98e-05	0.00301	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.95e-05	0.00299	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.93e-05	0.00297	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	3.88e-05	0.00293	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.84e-05	0.0029	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	3.79e-05	0.00286	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.66e-05	0.00277	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.63e-05	0.00275	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.61e-05	0.00273	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	3.58e-05	0.00271	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	3.42e-05	0.00259	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—COMT—attention deficit hyperactivity disorder	3.05e-05	0.00231	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MAOA—attention deficit hyperactivity disorder	3.03e-05	0.00229	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.94e-05	0.00222	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	2.39e-05	0.00181	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	2.38e-05	0.0018	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	2.36e-05	0.00178	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.82e-05	0.00138	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	1.67e-05	0.00126	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.63e-05	0.00123	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.59e-05	0.0012	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	1.53e-05	0.00116	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.5e-05	0.00113	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—EP300—attention deficit hyperactivity disorder	1.31e-05	0.00099	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	1.26e-05	0.000951	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.26e-05	0.000951	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	1.24e-05	0.000935	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.15e-05	0.00087	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.12e-05	0.000849	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	1.12e-05	0.000849	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	1.11e-05	0.000835	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.1e-05	0.000828	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.1e-05	0.000828	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.08e-05	0.000815	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.03e-05	0.000781	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.03e-05	0.000781	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.03e-05	0.000776	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.02e-05	0.000768	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.01e-05	0.00076	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1e-05	0.000758	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.79e-06	0.000739	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.58e-06	0.000724	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.45e-06	0.000714	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.98e-06	0.000678	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.77e-06	0.000662	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.55e-06	0.000646	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.34e-06	0.00063	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.26e-06	0.000624	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.86e-06	0.000594	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	7.63e-06	0.000576	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	7.57e-06	0.000572	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	7.34e-06	0.000555	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	6.81e-06	0.000514	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	6.76e-06	0.000511	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	6.76e-06	0.00051	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.76e-06	0.00051	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	6.65e-06	0.000502	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	6.64e-06	0.000502	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	6.6e-06	0.000498	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.55e-06	0.000495	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	6.26e-06	0.000473	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	6.22e-06	0.00047	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.18e-06	0.000467	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.4e-06	0.000408	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.14e-06	0.000388	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	4.09e-06	0.000309	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	4.06e-06	0.000307	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	3.27e-06	0.000247	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	2.92e-06	0.000221	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	2.85e-06	0.000215	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	2.68e-06	0.000203	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.76e-06	0.000133	CbGpPWpGaD
